Precision methylation biomarkers linked to cancer disparities

精确甲基化生物标志物与癌症差异相关

基本信息

批准号：
10201473
负责人：
Rafael Guerrero-Preston
金额：
$ 73.38万
依托单位：
LIFEGENE-BIOMARKS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-24 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10201473
关键词：
Acetic Acids Africa African American Baltimore Biological Assay Biopsy Blinded Cancer Center Cancer Death Rates Caribbean region Cervical Cervical Cancer Screening Cervical Intraepithelial Neoplasia Cervix carcinoma Clinical Colorectal Cancer Colposcopy Communities Country Cytology DNA DNA Sequence Data Developed Countries Developing Countries Disease Education and Outreach Emotional Epigenetic Process Evaluation Excision Genomics Genotype Glare Goals HPV-High Risk Health Health Care Costs Hour Human Human Papillomavirus Human papilloma virus infection Hysterectomy Incidence Innovation Corps Laboratory Research Latin American Latina Left Lesion Link Liquid substance Low income Malignant Neoplasms Malignant neoplasm of cervix uteri Methods Methylation Neighborhoods Oncogenic Pap smear Participant Patients Phase Pilot Projects Prospective Studies Protocols documentation Publishing Race Reflex action Retrospective Studies Risk Running Sampling Services Small Business Innovation Research Grant Specificity Squamous intraepithelial lesion Technology Testing Time Triage United States Vagina Validation Visual Woman Work arm base biomarker development bisulfite black women burden of illness cancer health disparity clinical risk commercialization cost feasibility testing follow-up health care quality improved instrument malignant breast neoplasm methylation biomarker mortality mortality disparity patient stratification prevent screening tumor validation studies

Acetic Acids Africa African American Baltimore Biological Assay Biopsy Blinded Cancer Center Cancer Death Rates Caribbean region Cervical Cervical Cancer Screening Cervical Intraepithelial Neoplasia Cervix carcinoma Clinical Colorectal Cancer Colposcopy Communities Country Cytology DNA DNA Sequence Data Developed Countries Developing Countries Disease Education and Outreach Emotional Epigenetic Process Evaluation Excision Genomics Genotype Glare Goals HPV-High Risk Health Health Care Costs Hour Human Human Papillomavirus Human papilloma virus infection Hysterectomy Incidence Innovation Corps Laboratory Research Latin American Latina Left Lesion Link Liquid substance Low income Malignant Neoplasms Malignant neoplasm of cervix uteri Methods Methylation Neighborhoods Oncogenic Pap smear Participant Patients Phase Pilot Projects Prospective Studies Protocols documentation Publishing Race Reflex action Retrospective Studies Risk Running Sampling Services Small Business Innovation Research Grant Specificity Squamous intraepithelial lesion Technology Testing Time Triage United States Vagina Validation Visual Woman Work arm base biomarker development bisulfite black women burden of illness cancer health disparity clinical risk commercialization cost feasibility testing follow-up health care quality improved instrument malignant breast neoplasm methylation biomarker mortality mortality disparity patient stratification prevent screening tumor validation studies

展开

项目摘要

Project Summary No woman should die of cervical cancer, yet cervical cancer is the third leading malignancy among women in the world, after breast cancer and colorectal cancer. Cervical cancer is also one of the tumors in which the most glaring disparities exist worldwide. Cervical cancer incidence and mortality has been higher for decades among Latinas in the United States (US). However, a recently published study revealed that cervical cancer death rates among White and Black women in the US are much higher than previously thought, after adjusting for the number of hysterectomies performed. Black women are dying from cervical cancer at a rate 77% higher than previously thought, and white women are dying at a rate 47% higher. The disparity in cervical cancer mortality rates by race doubled, from 2.7 to 5.4 per 100,000 women, after removing women with hysterectomies from mortality calculations. Presumably, the same is the case for Latina women, but there is currently no data available to verify if this is the case. The use of cytology screening (Pap smear) and oncogenic Human papilloma Virus (HPV+) genotyping are effective in identifying women who may be at risk for cervical cancer, but cannot be used to predict who is more likely to develop cervical carcinoma. Current standard of practice in the US for women with persistent HPV+ infection and abnormal Pap is referral to colposcopy and subsequent biopsy. However, most of these biopsies (55%-70%) are performed in women without clinical disease The goal of this project is to demonstrate the feasibility for the commercialization of the CervicalMethDx Test, a precision methylation for the cervical cancer screening space. We will focus on patients with persistent oncogenic Human Papilloma Virus (HPV+) infection, who are referred into colposcopy and subsequent biopsy, even when most will have a normal biopsy. We are partnering with David Sidransky's research laboratory to optimize the CervicalMethDx Test and with the Education and Outreach Department of the Johns Hopkins Sidney Kimmel Cancer Center to introduce precision epigenetic services to residents of low-income neighborhoods in Baltimore. Efficient triage of HPV+ women into colposcopy will decrease unnecessary biopsies, improve health care quality, decrease health care costs, and reduce existing cervical cancer mortality disparities in the US.

项目摘要没有女性应死于宫颈癌，但是宫颈癌是世界上女性中的第三次主要恶性肿瘤，仅次于乳腺癌和结直肠癌。宫颈癌也是最明显差异的肿瘤之一全世界。在美国（美国），拉丁裔数十年来，宫颈癌的发病率和死亡率一直更高。但是，最近发表的一项研究表明，在调整了进行的子宫切除术数量后，美国白人和黑人妇女的宫颈癌死亡率比以前想象的要高得多。黑人妇女因宫颈癌而死，比以前想象的高77％，而白人妇女的死亡率高47％。在从死亡率计算中删除了子宫切除术的妇女后，种族的宫颈癌死亡率差异从每100,000名妇女增加了一倍，从2.7人增加到5.4。据推测，拉丁裔妇女也是如此，但是目前尚无数据验证是否是这种情况。使用细胞学筛查（PAP涂片）和致癌的人乳头瘤病毒（HPV+）基因分型在有效确定可能有宫颈癌风险的女性，但不能用来预测谁更有可能发展宫颈癌癌。美国目前的实践标准，持续的HPV+感染和异常PAP的女性是转介到阴道镜检查和随后的活检。但是，大多数这些活检（55％-70％）在没有临床疾病的女性中进行该项目的目的是证明宫颈膜测试的商业化的可行性，这是一个精度宫颈癌筛查空间的甲基化。我们将重点关注具有持续性致癌性人乳头状瘤病毒（HPV+）感染的患者，即即使大多数人会进行正常的活检，他们也被转移到阴道镜和随后的活检中。我们正在与David Sidransky的研究实验室合作，以优化宫颈膜测试，并与Johns Hopkins Sidney Kimmel Cance Center的教育和外展部门一起向巴尔的摩低收入社区的居民引入精确表观遗传服务。 HPV+女性有效分类为阴道镜检查将减少不必要的活检，提高医疗保健质量，降低医疗保健成本，并降低美国现有的宫颈癌死亡率差异。